GBI Research Market Research Reports

Title published price

Antibacterial Therapies Drug Development Pipeline Review, 2017

By GBI Research

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within ...

22-Mar-2017 $3995

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

By GBI Research

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with t ...

21-Mar-2017 $3995

Cardiovascular Disorders Drug Development Pipeline Review, 2017

By GBI Research

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclero ...

16-Mar-2017 $3995

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

By GBI Research

Many countries are facing the challenge of an aging population, and there will be an increased number of people aged 60 and over - a high-risk age range for lung cancer. Over half of the incident cases of non-small cell lung cancer (NSCLC) are dia ...

09-Mar-2017 $4995

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

By GBI Research

Respiratory complications are a diverse set of indications that include respiratory disorders, cardiovascular disorders and infectious diseases. They are therefore associated with a broad range of underlying pathophysiology, which is reflected in ...

01-Mar-2017 $4995

Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

By GBI Research

Head and neck cancer (HNC) is the sixth most common malignancy worldwide, and its incidence is rising (Lacko et al., 2014). It represents a number of cancers that are known collectively as HNCs, and which usually begin in the squamous cells that l ...

01-Mar-2017 $6995

Colorectal Cancer - Heat Map and Analysis

By GBI Research

Summary Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It ...

01-Feb-2017 $2000

Parkinson's Disease - Heat Map and Analysis

By GBI Research

Summary Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairme ...

09-Jan-2017 $2000

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

By GBI Research

Summary The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a prono ...

09-Jan-2017 $4995

Non-Hodgkin Lymphoma - Heat Map and Analysis

By GBI Research

Summary Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 ...

06-Jan-2017 $2000

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

By GBI Research

Summary Immunology is a large therapy area characterized by disorders of the immune system - specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. D ...

05-Jan-2017 $6995

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

By GBI Research

Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly affects the skin, as cutaneous melanoma; however it can also affect other pigmented tissues, such as the eye or intestines, as ...

02-Jan-2017 $6995

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

By GBI Research

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particul ...

02-Jan-2017 $4995

COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

By GBI Research

Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people ...

01-Jan-2017 $4995

Dermatology Therapeutics Drug Development Pipeline Review, 2016

By GBI Research

Summary Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majorit ...

15-Dec-2016 $3995

Ophthalmology Drug Development Pipeline Review, 2016

By GBI Research

Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise. Although there are a number of treatments approved in ophthalmolog ...

01-Dec-2016 $3995

Diabetes & Obesity Drug Development Pipeline Review, 2016

By GBI Research

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, ...

01-Dec-2016 $3995

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

By GBI Research

Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and ...

01-Dec-2016 $6995

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

By GBI Research

Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of ...

01-Dec-2016 $4995

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

By GBI Research

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with t ...

01-Dec-2016 $4995